1. A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Issue 1 (1st November 2020) Authors: Rocchi, Serena; Tacchetti, Paola; Pantani, Lucia; Mancuso, Katia; Rizzello, Ilaria; di Giovanni Bezzi, Chiara; Scalese, Marco; Dozza, Luca; Marzocchi, Giulia; Martello, Marina; Barilà, Gregorio; Antonioli, Elisabetta; Staderini, Michela; Buda, Gabriele; Petrini, Mario; Cea, Michele; Quaresima, Mi... Journal: Hematological oncology Issue: Volume 39:Issue 1(2021) Page Start: 41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. (November 2019) Authors: Marcolin, Riccardo; Guolo, Fabio; Minetto, Paola; Clavio, Marino; Manconi, Lorenzo; Ballerini, Filippo; Carli, Alessandro; Passannante, Monica; Colombo, Nicoletta; Carminati, Enrico; Pugliese, Girolamo; Tedone, Elisabetta; Contini, Paola; Mangerini, Rosa; Kunkl, Annalisa; Miglino, Maurizio; Cagne... Journal: Leukemia research Issue: Volume 86(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biological Insights into Myeloma and Other B Cell Malignancies. (16th February 2016) Authors: Fulciniti, Mariateresa; Amodio, Nicola; Cea, Michele; Maiso, Patricia; Azab, Abdel Kareem Journal: BioMed research international Issue: Volume 2016(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Issue 1 (January 2023) Authors: Mina, Roberto; Musto, Pellegrino; Rota-Scalabrini, Delia; Paris, Laura; Gamberi, Barbara; Palmas, Angelo; Aquino, Sara; de Fabritiis, Paolo; Giuliani, Nicola; De Rosa, Luca; Gozzetti, Alessandro; Cellini, Claudia; Bertamini, Luca; Capra, Andrea; Oddolo, Daniela; Vincelli, Iolanda Donatella; Ronco... Journal: Lancet oncology Issue: Volume 24:Issue 1(2023) Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Issue 12 (December 2021) Authors: Gay, Francesca; Musto, Pellegrino; Rota-Scalabrini, Delia; Bertamini, Luca; Belotti, Angelo; Galli, Monica; Offidani, Massimo; Zamagni, Elena; Ledda, Antonio; Grasso, Mariella; Ballanti, Stelvio; Spadano, Antonio; Cea, Michele; Patriarca, Francesca; D'Agostino, Mattia; Capra, Andrea; Giuliani, Ni... Journal: Lancet oncology Issue: Volume 22:Issue 12(2021) Page Start: 1705 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. Issue 1 (2nd January 2020) Authors: Manconi, Lorenzo; Coviello, Elisa; Canale, Filippo; Giannoni, Livia; Minetto, Paola; Guolo, Fabio; Clavio, Marino; Marcolin, Riccardo; Cea, Michele; Cagnetta, Antonia; Gobbi, Marco; Miglino, Maurizio; Ballerini, Filippo; Lemoli, Roberto Massimo Journal: Leukemia & lymphoma Issue: Volume 61:Issue 1(2020) Page Start: 84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. (23rd January 2018) Authors: Minetto, Paola; Guolo, Fabio; Clavio, Marino; Kunkl, Annalisa; Colombo, Nicoletta; Carminati, Enrico; Fugazza, Giuseppina; Matarese, Simona; Guardo, Daniela; Ballerini, Filippo; Di Grazia, Carmen; Raiola, Anna M.; Cagnetta, Antonia; Cea, Michele; Miglino, Maurizio; Lemoli, Roberto M.; Gobbi, Marco Journal: British journal of haematology Issue: Volume 184:Number 3(2019) Page Start: 457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. Issue 1 (December 2015) Authors: Zucal, Chiara; D'Agostino, Vito; Casini, Antonio; Mantelli, Barbara; Thongon, Natthakan; Soncini, Debora; Caffa, Irene; Cea, Michele; Ballestrero, Alberto; Quattrone, Alessandro; Indraccolo, Stefano; Nencioni, Alessio; Provenzani, Alessandro Journal: BMC cancer Issue: Volume 15:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Evaluation of prognostic indices in elderly hospitalized patients. Issue 6 (15th June 2016) Authors: Monacelli, Fiammetta; Tafuro, Manuela; Molfetta, Luigi; Sartini, Marina; Nencioni, Alessio; Cea, Michele; Borghi, Roberta; Montecucco, Fabrizio; Odetti, Patrizio Journal: Geriatrics and gerontology international Issue: Volume 17:Issue 6(2017) Page Start: 1015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies. Issue 9 (1st September 2016) Authors: Cea, Michele; Soncini, Debora; Gobbi, Marco; Lemoli, Roberto M.; Cagnetta, Antonia Journal: Expert review of anticancer therapy Issue: Volume 16:Issue 9(2016) Page Start: 897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗